Pembrolizumab improved progression-free survival but not overall survival.
There was no improvement in overall survival.
Adding panitumumab to 5-fluorouracil and leucovorin improved progression-free survival.
Two nivolumab-based regimens improved survival over chemotherapy alone.
Researchers found that CROSS is not inferior to MAGIC/FLOT, supporting it’s place in decision making for patients with locally advanced esophageal cancer.
Nivolumab plus chemotherapy improved overall survival.
Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.
Adjuvant nivolumab prolonged distant metastasis-free survival.
An electronic monitoring system improved physical well-being and self-efficacy scores.
Some nongenetic risk factors for late-onset colorectal cancer may not be relevant for early-onset disease.
Patients treated with PARP inhibitors in clinical trials had a nearly 3-fold higher risk of pneumonitis than patients in control arms.
Radiation therapy alone was highly effective for the treatment of Helicobacter pylori–independent gastric mucosa-associated lymphoid tissue lymphoma.
Having a first-degree relative with colorectal polyps may increase a person’s risk of developing colorectal cancer, indicating that earlier screening is warranted.
Health-related quality of life tended to improve over time with pembrolizumab but not with chemotherapy.
Patients without comorbidities were less likely to undergo screening for colorectal cancer than patients with comorbidities.
A decrease in obesity rates may reduce the burden of gallbladder and biliary tract cancer worldwide, according to the results of a study.
The largest increase in cancer diagnosis at age 65 years was in stage I for all breast cancer, colon cancer, prostate cancer, and lung cancer.
A retrospective cohort study investigated the incidence of and risk factors for brain metastases in patients with colorectal cancer.
The trial found that the combination improved outcomes in patients with locally advanced rectal cancer compared with standard chemoradiotherapy, surgery, and adjuvant chemotherapy.
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.